Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125095478> ?p ?o ?g. }
- W2125095478 endingPage "25916" @default.
- W2125095478 startingPage "25897" @default.
- W2125095478 abstract "Esophageal adenocarcinoma (EAC) patients commonly present with advanced stage disease and demonstrate resistance to therapy, with response rates below 40%. Understanding the molecular mechanisms of resistance is crucial for improvement of clinical outcomes. IGFBP2 is a member of the IGFBP family of proteins that has been reported to modulate both IGF and integrin signaling and is a mediator of cell growth, invasion and resistance in other tumor types. In this study, high IGFBP2 expression was observed in a subset of primary EACs and was found to be significantly higher in patients with shorter disease-free intervals as well as in treatment-resistant EACs as compared to chemonaive EACs. Modulation of IGFBP2 expression in EAC cell lines promoted cell proliferation, migration and invasion, implicating a role in the metastatic potential of these cells. Additionally, knockdown of IGFBP2 sensitized EAC cells to cisplatin in a serum-dependent manner. Further in vitro exploration into this chemosensitization implicated both the AKT and ERK pathways. Silencing of IGFBP2 enhanced IGF1-induced immediate activation of AKT and reduced cisplatin-induced ERK activation. Addition of MEK1/2 (selumetinib or trametinib) or AKT (AKT Inhibitor VIII) inhibitors enhanced siIGFBP2-induced sensitization of EAC cells to cisplatin. These results suggest that targeted inhibition of IGFBP2 alone or together with either the MAPK or PI3K/AKT signaling pathway in IGFBP2-overexpressing EAC tumors may be an effective approach for sensitizing resistant EACs to standard neoadjuvant chemotherapy." @default.
- W2125095478 created "2016-06-24" @default.
- W2125095478 creator A5005499715 @default.
- W2125095478 creator A5006991208 @default.
- W2125095478 creator A5015860750 @default.
- W2125095478 creator A5030234836 @default.
- W2125095478 creator A5050357869 @default.
- W2125095478 creator A5050907642 @default.
- W2125095478 creator A5057943415 @default.
- W2125095478 creator A5063157880 @default.
- W2125095478 creator A5073835374 @default.
- W2125095478 creator A5082106342 @default.
- W2125095478 creator A5091311134 @default.
- W2125095478 date "2015-07-17" @default.
- W2125095478 modified "2023-10-13" @default.
- W2125095478 title "IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma" @default.
- W2125095478 cites W127913739 @default.
- W2125095478 cites W1491177143 @default.
- W2125095478 cites W1607110680 @default.
- W2125095478 cites W1747881616 @default.
- W2125095478 cites W177081501 @default.
- W2125095478 cites W1861705388 @default.
- W2125095478 cites W1904552623 @default.
- W2125095478 cites W1970330182 @default.
- W2125095478 cites W1972471610 @default.
- W2125095478 cites W1980591059 @default.
- W2125095478 cites W1984004506 @default.
- W2125095478 cites W1984824606 @default.
- W2125095478 cites W1987775895 @default.
- W2125095478 cites W1990540492 @default.
- W2125095478 cites W1991191152 @default.
- W2125095478 cites W2002476225 @default.
- W2125095478 cites W2005505016 @default.
- W2125095478 cites W2015614584 @default.
- W2125095478 cites W2017957497 @default.
- W2125095478 cites W2019629273 @default.
- W2125095478 cites W2021324583 @default.
- W2125095478 cites W2037592578 @default.
- W2125095478 cites W2041808638 @default.
- W2125095478 cites W2043863425 @default.
- W2125095478 cites W2049018598 @default.
- W2125095478 cites W2051483559 @default.
- W2125095478 cites W2058569715 @default.
- W2125095478 cites W2062014912 @default.
- W2125095478 cites W2065774446 @default.
- W2125095478 cites W2066562900 @default.
- W2125095478 cites W2067420381 @default.
- W2125095478 cites W2070058781 @default.
- W2125095478 cites W2082055110 @default.
- W2125095478 cites W2085521462 @default.
- W2125095478 cites W2087810003 @default.
- W2125095478 cites W2092645267 @default.
- W2125095478 cites W2093909277 @default.
- W2125095478 cites W2097029987 @default.
- W2125095478 cites W2103486910 @default.
- W2125095478 cites W2105516039 @default.
- W2125095478 cites W2107277218 @default.
- W2125095478 cites W2108131572 @default.
- W2125095478 cites W2109644220 @default.
- W2125095478 cites W2110946818 @default.
- W2125095478 cites W2112463023 @default.
- W2125095478 cites W2113579151 @default.
- W2125095478 cites W2116317289 @default.
- W2125095478 cites W2119294271 @default.
- W2125095478 cites W2119495536 @default.
- W2125095478 cites W2120339587 @default.
- W2125095478 cites W2122152342 @default.
- W2125095478 cites W2131301215 @default.
- W2125095478 cites W2135283463 @default.
- W2125095478 cites W2138083541 @default.
- W2125095478 cites W2145805608 @default.
- W2125095478 cites W2146675666 @default.
- W2125095478 cites W2150437708 @default.
- W2125095478 cites W2154444715 @default.
- W2125095478 cites W2158111765 @default.
- W2125095478 cites W2158843303 @default.
- W2125095478 cites W2159750196 @default.
- W2125095478 cites W2161395451 @default.
- W2125095478 cites W2163361061 @default.
- W2125095478 cites W2169694138 @default.
- W2125095478 cites W2169961966 @default.
- W2125095478 cites W2170066157 @default.
- W2125095478 cites W2170989872 @default.
- W2125095478 cites W2192080449 @default.
- W2125095478 cites W2219978888 @default.
- W2125095478 cites W2409607343 @default.
- W2125095478 cites W336115062 @default.
- W2125095478 cites W4247759091 @default.
- W2125095478 cites W86527326 @default.
- W2125095478 doi "https://doi.org/10.18632/oncotarget.4532" @default.
- W2125095478 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4694874" @default.
- W2125095478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26317790" @default.
- W2125095478 hasPublicationYear "2015" @default.
- W2125095478 type Work @default.
- W2125095478 sameAs 2125095478 @default.
- W2125095478 citedByCount "20" @default.
- W2125095478 countsByYear W21250954782017 @default.
- W2125095478 countsByYear W21250954782018 @default.